Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average): 2016-2024

Historic Shares Outstanding (Weighted Average) for Whitehawk Therapeutics (WHWK) over the last 9 years, with Dec 2024 value amounting to $24.6 million.

  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average) rose 91.46% to $47.1 million in Q3 2025 from the same period last year, while for Mar 2025 it was $46.8 million, marking a year-over-year increase of 90.54%. This contributed to the annual value of $24.6 million for FY2024, which is 0.50% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $24.6 million for FY2024, which was up 0.50% from $24.5 million recorded in FY2023.
  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $24.6 million during FY2024, with a 5-year trough of $3.1 million in FY2020.
  • For the 3-year period, Whitehawk Therapeutics' Shares Outstanding (Weighted Average) averaged around $24.5 million, with its median value being $24.5 million (2023).
  • Data for Whitehawk Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY soared of 565.25% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Whitehawk Therapeutics' Shares Outstanding (Weighted Average) stood at $3.1 million in 2020, then spiked by 565.25% to $20.9 million in 2021, then rose by 16.76% to $24.4 million in 2022, then climbed by 0.54% to $24.5 million in 2023, then climbed by 0.50% to $24.6 million in 2024.